Bacteria Engineered to Produce Serotonin Modulate Host Intestinal Physiology
ACS Synthetic Biology · 2024
DOI: 10.1021/acssynbio.4c00453 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Synthetic Biology, 2024. Verfasst von Chrystal F Mavros und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, Columbia University Irving Medical Center, New York, New York 10032, United States. Hauptthemen laut MEDLINE: Serotonin, Escherichia coli, Gastrointestinal Microbiome. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, NHGRI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Bacteria in the gastrointestinal tract play a crucial role in intestinal motility, homeostasis, and dysfunction. Unraveling the mechanisms by which microbes impact the host poses many challenges due to the extensive array of metabolites produced or metabolized by bacteria in the gut. Here, we describe the engineering of a gut commensal bacterium, Escherichia coli Nissle 1917, to biosynthesize the human metabolite serotonin for examining the effects of microbially produced biogenic amines on host physiology. Upon oral administration to mice, our engineered bacteria reach the large intestine, where they produce serotonin. Mice treated with serotonin-producing bacteria exhibited biological changes in the gut at transcriptional and physiological levels. This work establishes a novel framework employing engineered bacteria to modulate luminal serotonin levels and suggests potential clinical applications of modified microbial therapeutics to address gut disorders in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Biology, Columbia University Irving Medical Center, New York, New York 10032, United States.
- Department of Genetics and Development, Columbia University Irving Medical Center, New York, New York 10032, United States.
- Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby DK 2800, Denmark.
- Department of Nutritional and Metabolic Biology, Columbia University Irving Medical Center, New York, New York 10032, United States.
- Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York 10032, United States.
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York 10032, United States.
ORCID-Profile: Chrystal F Mavros, Morten O A Sommer, Harris H Wang
Förderung
- Wellcome Trust
- NHGRI NIH HHS
- NIAID NIH HHS
- NIDDK NIH HHS
- NIBIB NIH HHS
- Air Force Office of Scientific Research
- Novo Nordisk Fonden
- Office of Naval Research
Zitieren
APA
Mavros, C. F., Bongers, M., Neergaard, F. B. F., Cusimano, F., Sun, Y., Kaufman, A., Richardson, M., Kammler, S., Kristensen, M., Sommer, M. O. A., & Wang, H. H. (2024). Bacteria Engineered to Produce Serotonin Modulate Host Intestinal Physiology. ACS Synthetic Biology. https://doi.org/10.1021/acssynbio.4c00453
Vancouver
Mavros CF, Bongers M, Neergaard FBF, Cusimano F, Sun Y, Kaufman A, et al. Bacteria Engineered to Produce Serotonin Modulate Host Intestinal Physiology. ACS Synthetic Biology. 2024. doi:10.1021/acssynbio.4c00453
BibTeX
@article{Mavros2024,
author = {Mavros, Chrystal F and Bongers, Mareike and Neergaard, Frederik B F and Cusimano, Frank and Sun, Yiwei and Kaufman, Andrew and Richardson, Miles and Kammler, Susanne and Kristensen, Mette and Sommer, Morten O A and Wang, Harris H},
title = {Bacteria Engineered to Produce Serotonin Modulate Host Intestinal Physiology},
journal = {ACS Synthetic Biology},
year = {2024},
doi = {10.1021/acssynbio.4c00453}
}
EUVIMED